ClinicalTrials.gg
CompletedNCT01767428Updated Jan 14, 2013

Pharmacokinetic Study to Compare Two Formulations of Paracetamol

A Phase 1 interventional study of Paracetamol in Fever, Headache Disorders and Pain, sponsored by GlaxoSmithKline. Completed. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-14.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing acetaminophen in Fever — 1 open to participants now, 1 under way, none of them phase 3. Acetaminophen · Fever.

Enrollment
27th of 31
30 · median 100
Started
2010
with 3 others
Phase 1
3 of 31
none open now
Registered
17th of 31
by date
Lead sponsor
1 of 31
GlaxoSmithKline

Among the 31 studies testing acetaminophen in Fever, this one is the 27th largest by enrollment, is one of 4 that started in 2010, is one of 3 in phase 1, and was the 17th registered.

Fever

438 studies on the registry are indexed under Fever; 55 are open to participants now.

Browse Fever studies →

Open to participants now

1 of the 31 studies testing acetaminophen in Fever is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About acetaminophen

Acetaminophen: first FDA approval 1968 (NEOPAP). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 38 Fever studies recruiting now, 18 (47%) set no upper age limit and 14 (37%) stop at 75 or younger; 22 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing acetaminophen in Fever, or all of them as a file.
02

Study summary

A pharmacokinetic study in healthy volunteers comparing two formulations of paracetamol fast release in fasted state.

03

Conditions studied

  • Fever
  • Headache Disorders
  • Pain
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male volunteers aged 18-55yrs willing to give written for the study
  • must be within the range 18.5 - 24.9 kg/m\^2
  • Participant with a minimum weight of 50 kg

Exclusion criteria

Exclusion Criteria:

  • Participant with current or recurrent disease that could affect the action, absorption or disposition of the study medication or clinical or laboratory assessments (e.g. hepatic disorders, renal insufficiency, congestive heart failure)
  • Participant with known or suspected intolerance or to the study materials
  • Participant who are vegetarian
  • Participant smoking more than five cigarettes a day
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Experimental Paracetamol Tablet

    Experimental paracetamol tablet (500 milligrams \[mg\]) administered with 240 milliliters (mL) of water.

    Drug: Paracetamol

  • Active comparator
    Standard Paracetamol Tablet (500 mg)

    Standard paracetamol tablet (500 mg) administered with 240 mL of water.

    Drug: Paracetamol

Interventions

  • 500 mg immediate release paracetamol formulations

06

What researchers measure

Primary outcomes

  1. AUC (0-inf)

    Area under the plasma concentration time curve from zero and extrapolated to infinite time.

    Time frame: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

  2. Cmax

    Maximum plasma concentration of paracetamol.

    Time frame: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

  3. AUC (0-t)

    Area under the plasma concentration time curve from zero and extrapolated to the time of last quantifiable sample.

    Time frame: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

Secondary outcomes

  1. Tmax

    Time taken to reach maximum plasma concentration of paracetamol.

    Time frame: Blood samples drawn at 15 minutes pre-dose, then at 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 75, 90 minutes post dose and then at 2, 3, 4, 6, 8, 10, 12 hrs post dose.

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2010, a primary completion of Apr 2010 and a completion of Apr 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2012
First posted
Jan 14, 2013
Start
Apr 2010
Primary completionActual
Apr 2010
CompletionActual
Apr 2010
Last update
Jan 14, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 14, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01767428
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jan 14, 2013
Start date
Apr 2010
Primary completion
Apr 2010
Completion
Apr 2010
Last update
Jan 14, 2013

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion